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Abstract The HLA-G gene displays several peculiarities
that are distinct from those of classical HLA class I genes.
The unique structure of the HLA-G molecule permits a
restricted peptide presentation and allows the modulation
of the cells of the immune system. Although polymorphic
sites may potentially inﬂuence all biological functions of
HLA-G, those present at the promoter and 30 untranslated
regions have been particularly studied in experimental and
pathological conditions. The relatively low polymorphism
observed in the MHC-G coding region both in humans and
apes may represent a strong selective pressure for invari-
ance, whereas, in regulatory regions several lines of
evidence support the role of balancing selection. Since
HLA-G has immunomodulatory properties, the under-
standing of gene regulation and the role of polymorphic
sites on gene function may permit an individualized
approach for the future use of HLA-G for therapeutic
purposes.
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Introduction
Well-recognized biological features of the non-classical
class Ib HLA-G molecule that differ from other classical
class I HLA (-A, -B and -C) molecules include: (1) limited
protein variability, (2) presence of several membrane-
bound and soluble isoforms, generated by alternative
splicing of the primary transcript, (3) unique molecular
structure, presenting a reduced cytoplasmic tail, (4) mod-
ulation of the immune response, and (5) restricted tissue
expression. Polymorphic sites present in coding and non-
coding regions of the HLA-G gene may potentially affect
all of these biological features. Nucleotide variability in the
promoter or in the 30 untranslated region (30 UTR) may
inﬂuence HLA-G levels by modifying the afﬁnity of gene
targeted sequences for transcriptional or post-transcrip-
tional factors, respectively. Likewise, nucleotide variability
in the coding region may produce conformational changes
in the molecule, which may modify its major functions,
i.e., interaction with cell receptors, isoform production,
modulation of the immune response, polymerization fea-
tures and ability to couple peptides. In this section, we
highlight the major characteristics of HLA-G gene poly-
morphic sites that are relevant for the understanding of
molecule function, gene regulation and evolution, as well
as the implications of these features on selected disease
associations.
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Compared to classical HLA class I genes that exhibit
hundreds of alleles, the HLA-G locus presents only a few
variants. Due to the increasing number of reported HLA
alleles, much effort has been devoted to standardize HLA
nomenclature. Currently, an allele name may be composed
of four, six or eight digits. The ﬁrst two digits refer to the
allele family, and the third and fourth assign the order in
which the sequences were reported. Therefore, an allele
that differs in these ﬁrst four digits must have at least one
non-synonymous nucleotide substitution, i.e., modifying
the amino acid sequence of the encoded protein.
To date, 44 HLA-G alleles have been described, which
encode 14 distinct functional proteins with all isoforms
(HLA-G*0101, *0102, *0103, *0104, *0106, *0107,
*0108, *0109, *0110, *0111, *0112, *0114, *0115 and
*0116) and modiﬁed proteins encoded by the G*0105N
allele [1] (The International Immunogenetics Database-
IMGT/HLA, database version 2.28.0, January 2010).
Exemplifying, the HLA-G*0101 allele differs from G*0103
by a non-synonymous substitution at exon 2, codon 31,
position 292, where ACG codes for threonine and TCG
codes for serine. On the other hand, alleles exhibiting
synonymous nucleotide substitutions in the coding
sequence, producing no modiﬁcation of the amino acid
sequence of the encoded protein, are distinguished by the
use of the ﬁfth and sixth digits. The HLA-G*010401 and
G*010404 alleles are typical examples. Both alleles differ
at position ?1827 (codon 267), where the G*010401 allele
presents a CCG and the G*010404 allele a CCA, both
encoding the same residue of proline. Finally, distinct
nucleotide sequences observed in introns or in the 30 or 50
untranslated regions are distinguished by adding a seventh
or eighth digit. Exemplifying, the G*01010104 and
G*01010105 alleles encode the same protein sequence and
present the same coding sequence, except for a nucleotide
exchange in intron 1 at position 99, in which G*01010104
presents an adenine and G*01010105 a guanine. Other
examples can be retrieved from data illustrated in Fig. 1.
Although the nomenclature has been quite appropriate to
designate the adequate site of nucleotide substitution,
because of the ever-increasing number of HLA alleles,
particularly of the HLA-A and HLA-B loci, in which more
than 100 non-synonymous nucleotide substitutions have
been described for the same allele group, the WHO
Nomenclature Committee for Factors of the HLA System
has decided to introduce colons (:) into allele designations
to delimit the separate ﬁelds, to be used starting in April
2010 (Anthony Nolan Research Institute, http://hla.
alleles.org). Then, according to the new nomenclature,
the HLA-G*01010101 allele is designated as HLA-
G*01:01:01:01. Although the number of proteins encoded
by all HLA-G alleles is less than half the total number of
alleles, the discovery of nucleotide substitutions has been
continuously increasing, particularly those responsible for
synonymous substitutions. Therefore, only the new
nomenclature will be used throughout this review.
Due to the great number of synonymous nucleotide
variations in the coding region, only few encoded proteins
are described, accounting for HLA-G limited protein var-
iability. In contrast, many polymorphic sites in promoter
and 30UTR have been reported that may inﬂuence HLA-G
expression.
HLA-G coding region polymorphism: impact
on HLA-G molecule features
Similar to classical HLA class I molecules, HLA-G
presents a heavy chain, non-covalently associated with a
b2-microglobulin. The HLA-G gene also shows similarity
to the classical HLA loci, exhibiting 7 introns and 8 exons,
coding only the heavy chain of the molecule and located at
chromosome 6, whereas b2-microglobulin is encoded by a
gene at chromosome 15. Exon 1 encodes the peptide signal,
exons 2, 3 and 4, the extracellular a1, a2 and a3 domains,
respectively, and exons 5 and 6 the transmembrane and the
cytoplasmic domain of the heavy chain. Compared to
classical class I molecules, HLA-G has a shortened cyto-
plasmic domain because of the presence of a premature
stop codon in exon 6. Exon 7 is always absent from the
mature mRNA and, due to the stop codon in exon 6, exon 8
is not translated [2].
Based on the gametic phase (haplotypes) of 72 single
nucleotide polymorphisms (SNP) observed between exon 1
and intron 6, 44 HLA-G coding alleles were deﬁned
(IMGT, database 2.28.0, January 2010) (Fig. 1). Consid-
ering the region between exon 1 and exon 6, which encodes
the external portion and the transmembrane region of the
HLA-G molecule, all of these segments do present several
nucleotide variations [1]. The heavy chain encoding region
exhibits 33 SNPs; however, only 13 amino acid variations
are observed, 4 of them in a1, 6 in a2 and 3 in the a3
domain (Fig. 2). On the other hand, exons 1 and 5 both
present only two synonymous nucleotide substitutions,
hence the signal peptide and the transmembrane portion of
the molecule are invariable. Despite the limited protein
variability, amino acid substitutions may account for the
biological function of HLA-G, including peptide binding,
isoform production, and ability to polymerize and modulate
immune system cells.
Peptide-binding properties
Nucleotide variability in the coding region of the
HLA-G gene is evenly distributed throughout exons 2
370 E.A. Donadi et al.Fig. 1 Nucleotide sequences, from exon 1 to 4, described for the 44
alleles or haplotypes observed in the coding region of the
HLA-G gene (IMGT version 2.28.0, January 2010). Asterisks
represent that no ofﬁcial information regarding these single nucleo-
tide polymorphisms was available. Hyphen indicates deletion. Amino
acid codes: A alanine, S serine, F phenylalanine, Y tyrosine,
T threonine, M methionine, Q glutamine, R arginine, E glutamic
acid, P proline, H histidine, G glycine, D aspartic acid, V valine,
C cysteine, L leucine, I isoleucine, W tryptophan
Fig. 2 HLA-G a1, a2 and a3
domains. Variable amino acid
positions are indicated in blue
circles for each domain
(codons). The consensus amino
acids are based on the
*01:01:01:01 amino acid
sequence, and the amino acid
exchange for each coding-
region allele is given. Probably
G*01:13N is not expressed; all
domains of the G*01:05N may
be expressed. Based on IMGT
database version 2.28.0, January
2010. See also [12, 109]
HLA-G polymorphisms and functional implications 371(a1 domain), 3 (a2 domain) and 4 (a3 domain), as well as
in introns, contrasting with classical HLA class I genes, in
which nucleotide variation is clustered around the peptide-
binding groove encoded by exon 2 (a1 domain) and exon 3
(a2 domain), which inﬂuences peptide loading, peptide
diversity and T cell recognition.
Although both classical and non-classical HLA mole-
cules bind to peptides, HLA-G has a limited peptide
repertoire. Peptides isolated from placental cells revealed
that 15% of the HLA-G-bound peptides were derived from
a single cytokine-related protein [3], and peptides obtained
from transfected cells were derived from a restricted
number of proteins, including histone H2A, nuclear and
ribosomal proteins, and cytokine receptors [4, 5]. The
conformation of the HLA-G and bound peptide complex is
similar to that observed for classical molecules; however,
the peptide is buried deeper in the HLA-G cleft (reviewed
by Clements et al. [6]). Given these features of the HLA-G
peptide ensemble, and considering the absence of reported
HLA-G restricted T cells, peptide presentation is not the
major function of the HLA-G molecule. Apparently,
polymorphic sites around the peptide groove may not
inﬂuence this biological feature; however, the molecular
structure of the distinct HLA-G proteins coupled with
different peptides has not been fully investigated.
Membrane-bound and soluble isoforms
HLA-G presents 7 protein isoforms (Fig. 3), generated by
alternative splicing of the primary transcript, 4 of them
being membrane-bound (HLA-G1, G2, G3 and G4) and 3
soluble (G5, G6 and G7) isoforms. HLA-G1 is the com-
plete isoform exhibiting a structure similar to that of the
membrane-bound classical HLA molecule, associated with
b2-microglobulin. The HLA-G2 isoform has no a2 domain,
encoded by exon 3. HLA-G3 presents no a2 and a3
Fig. 3 Isoforms of HLA-G produced by alternative splicing of the
primary mRNA. The HLA-G heavy chain domains (a1, a2, a3,
transmembrane portion and cytoplasmic tail) are encoded by the
HLA-G gene (chromosome 6), and the light b2-microglobulin
molecule is encoded by a gene at chromosome 15. Exon 7 is always
spliced out. The ﬁnal portion of exon 6 and exon 8 is always
transcribed, however, never translated due to the presence of a
premature stop codon at the beginning of exon 6 (red stop signal), and
has been considered as the 30untranslated region of the gene (30UTR).
The primary transcript may be spliced out into 7 isoforms, HLA-G1 to
-G7. HLA-G1 is the full-length HLA-G molecule, HLA-G2 lacks
exon 3, HLA-G3 lacks exons 3 and 4, and HLA-G4 lacks exon 4.
HLA-G1 to -G4 are membrane-bound molecules due to the presence
of the transmembrane and cytoplasmic tail encoded by exons 5 and 6.
HLA-G5 is similar to HLA-G1 but retains intron 4, HLA-G6 lacks
exon 3 but retains intron 4, and HLA-G7 lacks exon 3 but retains
intron 2. HLA-G5 and -G6 are soluble forms due to the presence of
intron 4, which contains a premature stop codon at exon 4 (blue stop
signal), preventing the translation of the transmembrane and
cytoplasmic tail. HLA-G7 is soluble due to the presence of intron
2, which presents a premature stop codon (green stop signal). The
G*01:13N allele is probably not expressed due to the presence of a
premature stop codon at exon 2 (codon 54). A deletion of a cytosine
(DC) at exon 3 of the G*01:05N allele changes the reading frame,
leading to a stop codon at exon 4
372 E.A. Donadi et al.domains, encoded by exons 3 and 4. HLA-G4 has no a3
domain, encoded by exon 4. The soluble HLA-G5 and
HLA-G6 isoforms present the same extraglobular domains
of HLA-G1 and HLA-G2, respectively, generated by
transcripts conserving intron 4, which blocks the transla-
tion of the transmembrane domain (exon 5). The 50 region
of intron 4 is translated until the generation of a stop codon,
conferring to the HLA-G5 and HLA-G6 isoforms a tail of
21 amino acids implicated on their solubility. The HLA-G7
isoform has only the a1 domain linked to two amino acids
encoded by intron 2, which is retained in the corresponding
transcript. All alternative transcripts lack exon 7 [7–10].
Most of the currently described HLA-G alleles may the-
oretically produce, by alternative splicing, all membrane
boundandsolubleisoforms.Incontrast,theHLA-G*01:05N
(null allele, G*0105N) presents a cytosine deletion (DC) in
the last nucleotide of codon 129 or ﬁrst nucleotide of codon
130 in exon 3, causing a shift in the reading frame [11, 12],
leading to a downstream stop signal (TGA) in codon 189
(exon 4). As a corollary, this allele is associated with an
incomplete formation of the HLA-G1, -G4 and G5 isoforms
that possess the a3 domain, and normal expression of
HLA-G2, G3 and G7 isoforms that lack the a3 domain [12].
The other null allele, G*01:13N (G*0103N), presents a
C ? T transition at the ﬁrst base of codon 54 in exon 2 (a1
domain), yielding the formation of a premature stop codon
(TAG), which prevents the production of all membrane-
bound and soluble isoforms or produces presumably non-
functional proteins [13]. Figure 3 illustrates the major
features of HLA-G isoforms and major sites responsible for
physiological or truncated transcription patterns.
Polymerization
The presence of a cysteine residue at position 42 in the a1
domain of the heavy chain is a unique feature of the HLA-G
molecule, which permits the formation of dimers via a
Cyst42–Cyst42 intermolecular disulﬁde bond. Dimers may
be formed by recombinant HLA-G monomers, membrane-
bound and soluble molecules in transfected cells [14],
membrane-bound on the surface of cells that endogenously
expressHLA-G,andevenbyb2-microglobulin-freeHLA-G
constructs [15]. Once formed, the dimer has an oblique
orientation, exposing the binding sites for CD8 and leuko-
cyte immunoglobulin-like receptors B1/B2 (LILRB1/
LILRB2,alsoknownasLIR1/LIR2,ILT2/ILT4,andCD85j/
CD85d), permitting one HLA-G dimer to interact with two
LILR or CD8 molecules. Besides providing higher afﬁnity
for LILRs in relation to monomers, HLA-G dimers exhibit
enhanced LILR-mediated intracellular signaling [16].
None of the HLA-G alleles already described presents
nucleotide variation at codon 42 (TGT) that encodes the
cysteine residue. Therefore, apparently all alleles that
encode non-truncated HLA-G molecules may form dimers.
Since the dimer interface may be stabilized by electrostatic
and hydrogen-bond interactions, it is possible that nearby
polymorphic residues may inﬂuence dimer stability or alter
the ﬂexibility of the Cyst42–Cyst42 disulﬁde bond.
Modulation of the immune response
Several lines of evidence have supported the role of HLA-G
as a tolerogenic molecule, playing an important role in the
suppression of the immune response [2, 17]. Overall, all
segments of the molecule may contribute to this ability. The
short cytoplasmic tail retains HLA-G longer in the endo-
plasmic reticulum and prolongs the half-life of the molecule
on the cell surface because of the lack of an endocytosis
motif [18, 19], permitting multiple interactions with cells of
the immune system. The extracellular domains interact with
leukocyte receptors, including CD8, LILRB1 and LILRB2
and the killer cell immunoglobulin-like receptor KIR2DL4
(CD158d) [20, 21].
According to the nomenclature, KIR genes may encode
molecules exhibiting two (KIR2D) or three (KIR3D)
extracellular immunoglobulin-like domains, which may
contain immunoreceptor tyrosine-based inhibitory recep-
tor-ITIM (L-originally for long tail) or not (S-originally for
short tail) in the cytoplasmic domain. KIR genes with the
‘‘L’’ designation are predicted to be inhibitory receptors,
while those with ‘‘S’’ are predicted to encode activator
receptors. Besides, ‘‘S’’ genes contain in their transmem-
brane domain a positively charged arginine or lysine
residue. The KIR2DL4 gene is an exception, containing an
arginine in the transmembrane domain and a single ITIM in
the cytoplasmic domain. An array of activating and
inhibitor receptors is expressed on the surface of most NK
cells and macrophages, and the ﬁnal effector function
depends on the balance between activator and inhibitor
receptors [22]. Because of these features, the role of the
interaction of KIR2DL4 with HLA-G in the modulation of
the immune response has been a matter of much debate
[23, 24]. It has even been reported that cross-linking of
KIR2DL4 with a speciﬁc antibody or the incubation with
transfectants expressing HLA-G dimers upregulates several
pro-inﬂammatory cytokines [25]. Overall, the a1 domain of
HLA class I molecules is an important KIR recognition
site; however, the binding site of KIR2DL4 to HLA-G
remains unknown.
Since the Met76 and Gln79 residues are unique to
HLA-G, and since the mutation of these residues to Ala76/
79 affects the binding afﬁnity between KIR2DL4 and
HLA-G, these residues may be relevant candidates for this
interaction [26]. Although Met76 and Gln79 residues are
conserved in the a1 domain of all currently described
HLA-G variants, one KIR2DL4 allele (KIR2DL4*006) has
HLA-G polymorphisms and functional implications 373been associated with susceptibility to preeclampsia [27],
suggesting that both HLA-G and KIR polymorphisms may
be considered for functional studies.
LILRB1s are expressed on the surface of several leu-
kocytes, such as NK and lymphomononuclear cells, while
LILRB2s are primarily expressed on the surface of a
restricted set of cells, including monocytes and dendritic
cells [28]. Both LILRB1 and LILRB2 have several ITIM
receptors in their cytoplasmic tail, inhibiting signaling
events triggered by stimulatory receptors [29]. Both
receptors interact with classical HLA class I molecules;
however, the binding with HLA-G presents three- to
fourfold higher afﬁnity when compared to classical mole-
cules [30]. LILRB1 and LILRB2 bind to the a3 domain and
b2-microglobulin of the HLA-G molecule; however,
LILRB2 binds with higher afﬁnity than LILRB1. LILRB2
binds more to the a3 domain than to the b2-microglobulin
domain, and the binding sites of these receptors are dis-
tinct. The Tyr36 and Arg38 residues of LILRB2 bind to the
195–197 loop of the a3 domain of HLA-G, whereas the
Tyr38 and Tyr76 residues of LILRB1 bind to the Phe195 of
HLA-G [20]. Given that LILRBs are considered to be
the major HLA-G receptors, and since at least 4
HLA-G alleles (G*01:06, G*01:08, G*01:14 and G*01:16,
see Fig. 2) present non-synonymous polymorphic sites at
exon 4, which codes the a3 domain of the molecule, one
might expect that polymorphic residues observed in this
domain may inﬂuence LILRB interactions, modulating the
inhibitory intracellular signaling. It is interesting to observe
that the G*01:06 allele has been associated with pre-
eclampsia in French [31] and Singaporean populations
[32].
The CD8 molecule also interacts with the a3 domain of
classical and non-classical molecules, including HLA-G
and HLA-E, although exhibiting different afﬁnities. CD8a/
a binds to HLA-G with an afﬁnity comparable to that of the
HLA-A*02 interaction, contrasting with lower afﬁnity for
HLA-E. The afﬁnity of this interaction may vary according
to the considered allele. While most HLA-A alleles have
high afﬁnity for the a3 domain, HLA-A*68:01 and B*48:01
exhibit low afﬁnity. Mutation analyses of classical HLA
molecules have indicated that polymorphism at position
245 is responsible for this reduced afﬁnity. The major
differences between HLA-E and HLA-G in the a3 domain
reside at positions 219, 223 and 224 for HLA-E and 214
and 228 for HLA-G, which are located very close to the
HLA/CD8a/a interaction; i.e., the 223–229 loop of the a3
domain [21]. Although afﬁnity studies have not been per-
formed for variants of HLA-G molecules, those exhibiting
different residues in the a3 domain (see Fig. 2) may
potentially present diverse receptor afﬁnity. It is interesting
to observe that the a3 domain of HLA-G is the same site of
interaction with CD8a/a and LILRBs. Although CD8a/a
and LILIRB binding sites overlap, LILIRBs inhibit the
binding of CD8a/a to HLA molecules, indicating that the
inhibitory function of LILRBs may be dual, displacing
CD8a/a and activating ITIMs [30].
Besides the inhibitory role of HLA-G in cytotoxic cells
exhibiting CD8 on their surface, other interactions of HLA-
G molecules with CD8 cells deserve attention. Soluble
HLA-A-B-C and -G molecules can induce apoptosis in
CD8
? activated T lymphocytes as well as in CD8
? NK
cells (lacking the T cell receptor) at similar rates. The
binding of soluble HLA molecules to CD8 leads to apop-
tosis upregulating Fas production and Fas/FasL interaction
[33, 34]. Classical and non-classical soluble molecules may
produce similar effects on apoptosis of CD8
? cells; how-
ever, in conditions in which soluble HLA-G is elevated,
including pregnancy, some tumors and allografts with good
prognosis, this mechanism may represent an additional
immunomodulatory effect of HLA-G. Although the precise
mechanism of this interaction has not been elucidated, the
interaction of soluble forms of HLA-G containing the a3
domain seems to be plausible.
HLA-G non-coding region polymorphism: impact
on HLA-G expression regulation
The functional mRNA level of a particular gene is regu-
lated by the rate of synthesis, mainly driven by the
promoter region (50UTR) of a given gene, as well as by the
rate of degradation, stability, localization and translatabil-
ity of the speciﬁc mRNA [35]. Depending on the presence
of microenvironmental factors that may upregulate the
expression of HLA-G and depending on the genetic
background of the individual, theoretically, any tissue
might express HLA-G. Furthermore, HLA-G expression
may be proﬁtable or harmful, depending on the ﬁne
adjustment of the immune response. Pathological condi-
tions in which a vigorous and maintained immune response
is desirable, the expression of HLA-G is detrimental, like
in chronic viral disorders and cancer. In contrast, when a
vigorous immune response is undesirable, the expression of
HLA-G is proﬁtable, like in autoimmune disorders and
engraftment of allogeneic organs or tissues.
Many factors have been described that potentially affect
transcriptional and post-transcriptional mechanisms
responsible for HLA-G regulation [36]; however, the rea-
sons for HLA-G expression in some but not in other tissues
have not been fully elucidated. In this respect, the promoter
and 30untranslated regions exhibit numerous nucleotide
variations that may inﬂuence HLA-G expression and con-
sequently tissue distribution in healthy (placenta, thymus,
cornea, pancreas, proximal nail matrix, erythroblasts,
mesenchymal stem cells) and pathological conditions
(cancer, autoimmunity, transplantation). Besides, variation
374 E.A. Donadi et al.sites observed at introns 1–5 may be involved in HLA-G
regulation processes, such as alternative splicing.
HLA-G promoter region polymorphisms
Overall, classical HLA-class I genes contain two main
regulatory modules in the proximal promoter region (200
base pairs upstream of ATG), namely enhancer A (enhA)/
interferon-stimulated response element (ISRE) and SXY
[37] (Fig. 4, upper panel). EnhA comprises two palin-
dromic binding sites, kappa(j)B2 and jB1, for the NFjB/
rel family members [38], and ISRE, a target site for the
interferon regulatory factor family, including the interferon
regulatory factor-1 (IRF-1) [39]. SXY comprises the X1,
X2 (site a) boxes and Y box (also named enhancer B),
bound by the multiprotein complex regulatory factor X
(RFX) [comprising RFX5, RFX-associated protein
(RFXAP) and RFX-ankyrin(ANK)/B] [40–43], X2 box-
binding protein (X2-BP)/cAMP response element-binding
(CREB) [44] and nuclear factor Y (NF-Y) [45]. All these
factors cooperate to allow the formation of a stable
multiprotein complex and the binding of the class II
transactivator (CIITA), which mediates constitutive
and IFN-c-induced expression of HLA-class I molecules
[46, 47]. S box function is not fully understood and could
possibly play a role in the promoter architecture [48]
The HLA-G promoter region is unique among the HLA
genes with a divergent proximal region when compared to
the other HLA genes [49]. A modiﬁed enhA and a deleted
ISRE render the proximal HLA-G gene promoter unre-
sponsive to NF-jB[ 38] and IFN-c [39]. The upstream
region encompassing the SXY module only contains
conserved S and X1 sequences. While the X1 box was
shown to be a potential target for the RFX5 factors by
electrophoretic mobility shift assay [50], chromatin
immunoprecipitation assay analysis demonstrated that
RFX5 is not associated with the HLA-G promoter in situ
[51].
A few alternative regulatory elements within the
HLA-G gene promoter have been described. Using HLA-G
transgenic mice, a 244-bp positive regulatory region loca-
ted -1.2 kb from the ATG initiation codon of the
HLA-G gene is critical for its spatio-temporal expression,
presenting a function similar to that of the locus control
region (LCR) [52, 53]. The CREB1 factor binds to this
region (-1380/-1370), as well as to two additional cAMP
response elements (CRE) dispersed through the promoter
region at positions -934 and -770 from the ATG,
Fig. 4 Upper panel
Comparison of cis-regulatory
elements of classical HLA-class
I and HLA-G proximal promoter
regions (200 base pairs
upstream of ATG). Dotted
boxes with slashes indicate
mutated regulatory elements in
the HLA-G promoter. Mutations
prevent binding of major
classical HLA-class I
transacting factors. RFX
complex binds to the conserved
HLA-G X1 box in
electrophoretic mobility shift
assay but is not associated to the
HLA-G promoter in situ. Lower
panel Single nucleotide
polymorphisms along the whole
HLA-G gene promoter sequence
(1.4 kb upstream of ATG) as
well as the location of the
known regulatory elements
HLA-G polymorphisms and functional implications 375allowing promoter transactivation with the co-activators
CREB binding protein (CBP)/P300 [54]. In addition, an
ISRE motif, which is highly homologous to the consensus
ISRE, is located at position -744 bp upstream of ATG
[55], beside a nonfunctional GAS-like element (-734)
[56]. ISRE is a binding site for IFN-response factor-1 (IRF-
1) and transactivates HLA-G expression following IFN-b
treatment [55]. A heat shock element (HSE) is located
within the HLA-G promoter at position -459/-454 that
binds heat shock factor 1 (HSF-1) [57]. Librach’s group
identiﬁed a binding site for the progesterone receptor
located -37 bp from ATG that is overlapping the HLA-
G TATA box [58]. Finally, the ras responsive element
binding 1 factor (RREB-1) was recently demonstrated to
downregulate HLA-G transcriptional activity through three
ras response elements (RREs) along the HLA-G gene
promoter (-1356, -142, -53) [59]. RREB-1 is likely to
act through the recruitment of C-terminal binding protein
(CtBP) implicated on chromatin remodeling [60].
Contrary to expectations, the HLA-G promoter exhibits
numerous variations since 29 SNPs have been identiﬁed to
date [61–63]. They may be of importance in the regulation
of HLA-G expression and may act in different ways.
Interestingly, many of these polymorphisms either coincide
with or are closed to the known regulatory elements
described above, and thus may affect the binding of the
corresponding regulatory factors (Fig. 4, lower panel).
Based on this assumption, polymorphisms have been
identiﬁed in the LCR. Regarding -725 G/C/T SNP, the
three haplotypes were cloned into luciferase expression
vectors and transfected into JEG-3 cells, resulting in a
signiﬁcantly higher expression level of the promoter hap-
lotype containing the -725G allele compared with those
containing the -725C or -725T alleles [64]. Of note is
that the -725 G/C/T SNP is very close to ISRE. Along this
line, polymorphism in the proximal promoter of Paan-AG,
the functional homologue of HLA-G in the olive baboon,
was shown to inﬂuence NF-jB binding and transcriptional
activity [65]. In addition, evidence has been accumulated
showing that the methylation status of the HLA-G gene
promoter is crucial to the transcriptional activity of the
gene [66, 67]. One may speculate that promoter methyla-
tion might also be affected by polymorphisms located at
CpG sites [64]. Finally, in some cases, polymorphism in
the promoter region may be in linkage disequilibrium with
30 UTR variants [68], and some of them could inﬂuence
alternative splicing [69] and mRNA stability [70].
Interestingly, the pattern of variations observed in the
HLA-G promoter region is characterized by two divergent
lineages, which is consistent with balancing selection.
Ober’s group proposed that it was probably related to
highly regulated expression favoring high- and low-
expressing promoters under temporally and/or spatially
varying selective pressures [61]. Therefore, this should be
considered as a very pertinent parameter in the under-
standing of HLA-G gene regulation and more particularly
in some HLA-G-associated diseases. So far, only a few
studies have addressed these issues. One study performed
in Chicago families and in a Dutch population demon-
strated that the GG genotype in SNP -964 G/A was
associated with asthma in children of affected mothers,
whereas the AA genotype was associated with asthma in
children of unaffected mothers [68]. Another study asso-
ciated the -725G variant with sporadic miscarriage [71],
but, contrary to expectation, this variant was found to be
associated with increased HLA-G transcription [71]. Other
studies did not reveal any signiﬁcant association with HLA-
G promoter polymorphism, levels of HLA-G and diseases.
No association was observed between -56 C/T polymor-
phism and preeclampsia (n = 118) and eclampsia (n = 46)
[72], or between -725 C/G/T polymorphism with sus-
ceptibility to multiple sclerosis (MS) and the course of MS
(n = 698) [73]. Therefore, additional and larger studies
encompassing several polymorphisms of the HLA-G pro-
moter region in various diseases are required for a
deﬁnitive conclusion. Further functional analysis may
complete this scenario.
HLA-G 30 untranslated region (30UTR) polymorphisms
Since exon 7 is always absent from the mature mRNA and,
due to the stop codon in exon 6, exon 8 is not translated,
this gene segment has been considered to be the 30UTR of
the mature RNA. The HLA-G 30UTR contains several
regulatory elements [35], including polyadenylation signals
and AU-rich elements [74], as well as signals that regulate
the spatial and temporal expression of an mRNA [35]. The
primary transcripts must be processed and bound by pro-
teins before being exported to the cytoplasm [75]. In this
process, the Cap protein is added, introns are removed by
the spliceosome, and the 30 ends are cleaved and poly-
adenylated. The Cap-binding complex (CBC) binds to the
50 monomethylated cap structures and poly(A)-binding
proteins (PAB) to the 30 tail in order to export competent
messenger ribonucleoprotein particles (mRNPs) necessary
to mRNA transportation and translation [35, 75]. The
proteins that bind to an mRNA can inﬂuence its translation,
localization and degradation, and any polymorphism at
30UTR of a given gene may inﬂuence the binding proper-
ties. The availability of the mRNA for translation is
constantly balanced by the opposing force of mRNA
retention and decay, in which non-functional and delete-
rious transcripts may be eliminated before translation [35,
75–77] (for a detailed review regarding the 30UTR trans-
lational control see [35]). In addition, a 30UTR of a given
gene may be a target for microRNAs (miRNAs), which are
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processed from longer precursors. miRNAs may negatively
regulate gene expression by translation suppression, RNA
degradation or both [35, 78]. The ﬁrst miRNA was reported
in 1993 [79], and more than 600 have been reported to date
[80].
Before going to the HLA-G 30UTR polymorphisms, it
should be mentioned that there is no consensus in the lit-
erature regarding the position of the nucleotide variation in
this region. As reported by IMGT, the ﬁrst nucleotide of
the coding sequence of the HLA-G gene is the adenine of
the ﬁrst codon at exon 1 (ATG), extending the sequence
until position 2838 at intron 6. Since there is no ofﬁcial
information beyond this point, nucleotide positions that we
and other authors have used [78, 81, 82] infer polymorphic
sites at 30UTR using the original HLA-G sequence descri-
bed by Geraghty et al. [83], considering the ﬁrst base the
adenine of the ﬁrst ATG codon at exon 1, as well as public
sequences reported for chromosome 6. On the other hand,
other authors have used the original sequence described by
Geraghty et al. [83], including part of the promoter
sequence, a region encompassing 781 nucleotides before
the ﬁrst ATG. Currently, more than 1,500 nucleotides are
considered to be the promoter sequence, and 781 bases
represent only an aleatory fragment of the promoter region
base sequence, as originally reported in 1987. Therefore,
these authors refer to 30UTR polymorphisms encompassing
these 781 base pairs. In addition, the original sequence
described by Geraghty et al. does not consider the 14 base
pair (bp) insertion, since the sequenced allele was
G*01:01:01:01, which has a 14-bp deletion. Given that 14-
bp insertion or deletion allele frequencies are closely
similar in several populations, and given that the insertion
allele is present in gorillas and chimpanzees, probably
representing the ancestor allele, the 14-bp sequence should
be included in the sequence, as considered by us and other
authors [78, 81, 82]. Therefore, the nucleotide variation
sequence considered from the ﬁrst ATG codon at exon 1,
including the 14-bp insertion, seems to be the more
appropriate form to assign 3’UTR polymorphisms. For
instance, the SNP at the ?3010C/G position is considered
by other authors as ?3777, i.e., 3010 plus 781 (aleatory
part of the promoter region) minus 14 bp (a segment absent
in the allele described by Geraghty et al.).
The HLA-G gene exhibits a 30UTR presenting AU-rich
motifs, a poly-A signal, and several polymorphic sites that
may potentially inﬂuence HLA-G transcription, translation
or both by several different mechanisms. Among them, it is
worth mentioning: (1) the presence (insertion) or absence
(deletion) of a 14-bp fragment (INDEL polymorphism),
which has been associated with mRNA stability, (2) the
SNP at the ?3142 position, which may be a target for
certain miRNAs, degrading HLA-G mRNA, and (3) the
SNP at the ?3187 position, which is related to mRNA
stability and degradation. Figure 5 illustrates the 30UTR of
the HLA-G gene, emphasizing the polymorphic sites that
may inﬂuence HLA-G expression.
Although the 14-bp INDEL polymorphism has been
associated with the magnitude of HLA-G production [84],
modulating HLA-G mRNA stability [70, 85–87], the
mechanisms implicated have not been elucidated.
HLA-G alleles presenting the 14-bp (50-ATTTGTTCA
TGCCT-30) sequence [88] have been associated with lower
mRNA production for most membrane-bound and soluble
isoforms in trophoblast samples [87, 89]. On the other
hand, a fraction of HLA-G mRNA transcripts presenting
the 14-base insertion can be further processed (alterna-
tively spliced) by the removal of 92 bases from the mature
HLA-G mRNA (Fig. 4)[ 85, 87], yielding smaller HLA-G
transcripts, reported to be more stable than the complete
mRNA forms [70]. The ratio between -92 and ?92 base
transcripts may vary according to the cell line studied,
being 0.5 for JEG-3 cells (that endogenously produces
HLA-G) and 0.2 for transfected M8 melanoma cells [70].
This alternative splicing is probably not only driven by the
presence of the 14-base fragment in the primary transcript
and may be a consequence of the presence of other poly-
morphisms in linkage disequilibrium with the 14-bp
insertion. In fact, JEG-3 cells are homozygous for the
G*01:01:03 allele, and M8 cells are transfected with the
G*01:01:02 allele, both presenting nucleotide differences
in exons 3 and 5, and also in introns 1 and 4. In addition,
both G*01:01:03 and G*01:01:02 alleles are associated
with different 3’UTR haplotypes that differ at the ?3035,
?3187 and ?3196 positions, all preserved after the alter-
native splicing [82, 90]. In conclusion, the combination of
such polymorphisms, encompassing the coding region and
30UTR, may inﬂuence the amount of primary 14-base
insertion transcripts that lose the 92-base sequence.
The nucleotide variation at the ?3142 position (Fig. 5)
was recently explored by Tan et al. [81], who demonstrated
that this marker may be related to susceptibility to asthma as
well as inﬂuencing HLA-G expression. The presence of a
guanine at the ?3142 position may inﬂuence the expression
of the HLA-G locus by increasing the afﬁnity of this region
for the microRNAS miR-148a, miR-148b and miR-152,
therefore decreasing the mRNA availability by mRNA
degradation and translation suppression. The inﬂuence of
the ?3142G allele was demonstrated by a functional study
in which HLA-G high-expressing JEG-3 cells were trans-
fected with miR-148a, decreasing soluble HLA-G levels. In
addition, the miRNAs miR-148a and miR-148b were
detected in bronchial epithelial cells but were underrepre-
sented in the cytotrophoblast cells, which is in agreement
with the higher expression of HLA-G in cytotrophoblast in
relation to bronchial epithelial cells. Similarly to miR-142a,
HLA-G polymorphisms and functional implications 377miR142b and miR-152, an in silico analysis has revealed
that several humanmiRNAs have the potential to bind to the
HLA-G mRNA 30UTR and inﬂuence HLA-G expression.
The binding ability of these miRNAs may potentially be
inﬂuenced by several polymorphisms present in the HLA-
G 30UTR, emphasizing the role of the 14-bp fragment, SNPs
at the ?3003, ?3010, ?3027 and ?3035 positions, which
encompass a region of only 32 nucleotides that may inﬂu-
ence the binding of several miRNAs, and the ?3142 SNP,
as previously discussed [90].
A recent study has reported that the presence of an
adenine at the ?3187 position is associated with pre-
eclampsia in a Canadian population [91]. This SNP is near
(4-bp upstream) an AU-rich motif that mediates mRNA
degradation. The same report demonstrated that this SNP is
associated with decreased RNA stability in vitro, and the
presence of the ?3187A allele may lead to a decreased
HLA-G expression [91].
These three polymorphic sites associated with HLA-G
production may also be associated with each other, illus-
trating a scenario in which their inﬂuence may not be
mutually exclusive. It is noteworthy that the 14-bp inser-
tion is always accompanied by the ?3142G and ?3187A
alleles, both previously associated with low mRNA avail-
ability, indicating that the low mRNA production
associated with the 14-bp insertion [87] may also be a
consequence of the presence of these polymorphisms
associated with the 14-bp fragment [82].
In addition to the described variation sites discussed
above, the 30UTR presents several other polymor-
phisms frequently observed in highly genetically diverse
populations [82, 92], which have not been associated with
differential HLA-G expression so far, as illustrated in
Fig. 5. The polymorphic sites at the 30UTR seem to be
arranged in several haplotypes, each of them associated
either with a single or a group of coding and promoter
region polymorphisms [74, 82], creating an extended HLA-
G haplotype. Exemplifying, the ?3003C allele is associ-
ated with other 30UTR variation, including the 14-bp
deletion, ?3142C and ?3187A alleles, as well as the
coding region nucleotide variation typical of the
G*01:01:01:05 allele, and further with a speciﬁc promoter
region polymorphism [82].
In conclusion, in contrast to the coding region, the
30UTR of the HLA-G locus presents a high degree of var-
iation, presenting several polymorphic sites that may
potentially inﬂuence mRNA stability, turnover, mobility
and splicing pattern. The expression of HLA-G is a com-
plex process modulated by many factors such as the
promoter efﬁciency, driven by 50 promoter polymorphisms,
and the rate of mRNA degradation or translation, highly
inﬂuenced by the mRNA 30UTR polymorphisms. Although
several polymorphisms in the HLA-G 30UTR have been
previously related to mRNA stability or degradation, their
inﬂuence seems to occur simultaneously since these alleles
are characteristically associated in haplotypes.
Evolution aspects of HLA-G
To understand the mechanisms that generated diversity at
the HLA-G locus, some evolutionary aspects observed in
Fig. 5 Variation sites, described by us and by other authors, observed
in the HLA-G 30 untranslated region, which may inﬂuence HLA-G
expression. The frequencies of some of these polymorphic sites
observed in a highly heterogenous population such as Brazilians are
also shown. a Castelli et al. [82]. b Hviid et al. [87]. c Hiby et al. [85].
d Rousseau et al. [70]. e Alvarez et al. [74]. f Unpublished data. This
SNP was found in the Brazilian population in only two individuals.
g Tan et al. [81]. h Yie et al. [91]
378 E.A. Donadi et al.New and Old World primates, in Pongidae and in humans
are emphasized, including the genetic diversity of the
HLA-G locus in worldwide populations.
To avoid misunderstandings regarding the primate
Major Histocompatibility Complex nomenclature, the
general abbreviation MHC-G will be used to assign the
HLA-G homologous locus. A similar approach will be used
for other MHC loci.
New World primates
Considering the lineage that gave rise to Old World and
anthropoid monkeys, the New World monkey lineage
separated about 38 million years ago (mya). The cotton-top
tamarin (Saguinus oedipus, Saoe) that inhabits the Central-
South American continent (Costa Rica, Panama, Colom-
bia) is a typical example of this group. Saoes presumably
have functional MHC-G-like genes instead of MHC-A and
-B genes [93]. MHC-C sequences have also been detected
([94], Fig. 6), which may strongly interact with KIRs [95].
Saoes share more sequence homologies with HLA-G than
with classical HLA class I genes [93, 96]. Thus, it has been
proposed that HLA-G could be the ancestral MHC class I
gene and that MHC class I genes of the Saoes could be
homologous to the HLA-G locus. On the other hand, it has
also been shown that MHC-E may be more similar to Saoe
MHC (Fig. 7) when MHC-G and, in addition, MHC-E are
analyzed together [95, 97].
MHC-G intron 2 sequences show conserved motifs in all
primate species studied so far, particularly a 23-bp deletion
between positions 161 and 183, which seems to be locus
speciﬁc [97, 98]; however, the Saoe MHC-G intron 2 does
not bear this deletion (Fig. 8), which is surprising. The two
most feasible explanations for this phenomenon could be
that: (1) the MHC-G-like sequences in Saoe described did
not give rise to the Old World monkey and human MHC-G
alleles, or (2) the 23-bp deletion (Fig. 8) most likely
occurred after separation of the New World:Old World
monkey lineages about 38 mya. The ﬁrst hypothesis is
more plausible since eluted peptides from cotton-top tam-
arin MHC-G like molecules are not typical of MHC-G [G.
Rammansee, personal communication, 4]).
On the other hand, Saoe usually gives birth to mono-
zygotic twins after 4–5 months of pregnancy and,
thereafter, their fathers take care of the newborns until they
Fig. 6 New World monkeys: the cotton-top tamarin (Saguinus
oedipus, Saoe) MHC-C. Two different MHC-C sequences have been
found (GenBank accession numbers AF005217 and AF005218),
which cluster with other primates MHC-C. This is represented in a NJ
dendrogram. HLA human MHC, Patr chimpanzee, Gogo gorilla, Popy
orangutan, Hyla gibbon, Mamu M. mulatta
Fig. 7 The MHC-G DNA sequence of cotton-top tamarins (Saoe) is
more closely related to the primate MHC-E than to the primate MHC-
G sequence in the NJ tree (shown), also regarding DNA base
percentage similarity (not shown). HLA human MHC, Patr chimpan-
zee MHC, Gogo gorilla MHC, Popy orangutan MHC, Hyla gibbon
MHC, Mamu M. mulatta
HLA-G polymorphisms and functional implications 379are weaned and only give them to their mother for feeding
[99]. Whether or not this peculiar pregnancy is related to
the peculiar MHC-G system of this species has to be
determined. Due to the high polymorphism observed in
Saoe MHC-G molecules (11 alleles) (Fig. 9), it is possible
that these G-like molecules are classical antigen-presenting
molecules in New World monkeys since no other class I
MHC molecules have been found, except one that seems to
be MHC-C, not known to be translated into protein [94, 95,
100].
In conclusion, many MHC-G-like molecules exist in
monkey species that separated from the human lineage at
least 38 mya. Since MHC-G alleles present polymorphic
sites at the T cell receptor, NK receptor and antigen
binding sites, it is likely that the MHC-G function of these
New World monkeys is similar to classical HLA class I
presenting molecules.
Old World primates (Cercopithecinae subfamily)
This group of monkeys lives in Eurasia and Africa. Their
pregnancies last 5 months, and they usually deliver just one
newborn. The MHC-G alleles of M. mulatta (Mamu, rhesus
monkey), M. fascicularis (Mafa, cynomolgous monkey)
and C. aethiops (Ceae, green monkey) all bear stop codons
in a very restricted area of exon 3 (at codon 164), and some
alleles may also show stop signals at codons 133, 118 and
176 ([101], (Fig. 10). The a1 domain of the molecule is
always preserved in all species studied and may sufﬁce for
MHC-G function in Cercopithecinae. Considering the
Fig. 8 MHC-G intron 2 nucleotide sequences compared to other
MHC sequences (see also [98, 101]. The box indicates the 23-bp
deletion observed in all introns 2 from MHC-G sequences. Cotton-top
tamarins (Saoe) do not show this typical deletion, and this feature
further casts doubts about whether the described cotton-top tamarin’s
majority MHC alleles belong to the MHC-G lineage. Otherwise, this
deletion may have appeared in the Old World monkey’s lineage. Saoe
intron 2 sequence belongs to Saoe-G*02 and -G*04 alleles, which
were sequenced in three different monkeys. Identity between residues
is indicated by a dash and deletions are denoted by an asterisk
380 E.A. Donadi et al.postulated role of MHC-G in preserving the fetus from
maternal NK cell attack, and considering that the preg-
nancies are normal, usually bearing just one fetus,
functional MHC-G molecules may exist in these species
lacking the a2 domain. Otherwise, the existence of reading-
through stop codon mechanisms may be present, as found
in certain mammalian genes [102–104].
A total of 43 Cercopithecinae individuals were tested
for the presence of a stop codon at position 164, and it was
observed in all of them. This is a general feature of this
subfamily, which may have occurred before speciation
within the group precursors (at least 30 mya, when they
separated from higher primates, Hylobates and Pongidae).
Stop base triplets have also been reported in humans at
codon 107, and the presence of a cysteine at codons 101
and 164, crucial to maintain the overall molecule tertiary
structure, has also been found to be substituted by another
amino acid [101]. All these variations were observed in a
heterozygous form. In these species, mothers are exposed
to relatively few allogeneic fetuses since 92% of preg-
nancies have the a-male as a father [99].
In conclusion, only postulated isoforms not bearing the
a2 MHC-G domain are found in Cercopithecinae monkeys
due to the existence of stop codons in homozygosis mainly
at position 164, although other stop codon positions are
observed. These mutations appeared in the Cercopitheci-
nae common ancestors after the separation from the human
and Pongidae lineages about 35 mya. Either a2-lacking
MHC-G isoforms may sufﬁce for function or all isoforms
may be possibly due to stop codons reading-through
mechanisms.
Pongidae
Gorillas and chimpanzees (Figs. 11a, b) do not seem
to have high polymorphism at MHC-G; however, more
individuals need to be studied. The almost non-existence
of nucleotide variation parallels the relatively low
Fig. 9 Saoe (cotton-top
tamarins) MHC-G clusters in
relatedness dendrograms with
MHC-E of other primates
(see Fig. 7)
Fig. 10 Macaca mulatta. MHC-G exon 2 and exon 3 sequences,
showing two stop codon positions at exon 3 (TGA) (ﬁve individuals
were studied). Macaca fascicularis (four individuals) and Cercopi-
thecus aethiops (ﬁve individuals) also showed stop codons at MHC-G
exon 3. All of these monkeys belong to the Cercopithecinae family
and show one stop codon at the 164 position. Some other Macaca
species (43 individuals were studied) show additional stop codons at
118, 133 and 176 exon 3 residues [101]
HLA-G polymorphisms and functional implications 381polymorphism seen in humans (see Fig. 2)[ 98, 105].
Mothers show relatively high exposure to allogeneic fetu-
ses due to polygamy [99]. However, the orangutan
(Fig. 11c) shows ﬁve encoded proteins that affect both the
T cell receptor and the antigen binding site. Thus, the very
low MHC-G polymorphism may only have appeared 15
mya, when the orangutan diverged from the human lineage.
Orangutans may show long lasting male-female relation-
ships that expose mothers to relatively few allogeneic
fetuses [99].
In conclusion, orangutans that separated from the human
lineage about 15 mya show more MHC-G alleles than
gorillas and chimpanzees, exhibiting variability at the T
cell receptor, NK and antigen binding sites.
Humans
Similar to gorilla and chimpanzee, humans also present low
coding region polymorphisms, encoding only 14 common
proteins. Many Negroid, Caucasoid and Mongoloid indi-
viduals have been studied [98, 105] (Table 1), yielding
sound results. The allelism apparently does not drastically
affect the HLA-G molecule function. According to these
data, the coding-region of the HLA-G gene seems to suffer
a strong selective pressure for invariance (purifying
selection), i.e., preservation of nucleotide and amino acid
sequences, reduced variability and lower than expected
non-synonymous mutation rate [106]. However, humans
bearing the null allele (G*01:05N) in homozygosis have
been found [107–109], which may indicate that soluble
HLA-G molecule or molecules lacking the a3 domain are
sufﬁcient for HLA-G function.
The selective forces acting at the promoter region and
30UTR of the HLA-G gene seem to be different from those
acting at the coding region. The pattern of variation of the
promoter region is characterized by two divergent lineages
of haplotypes, which has been maintained by balancing
selection in worldwide human populations studied so far.
These lineages may have different promoter activity and
may modulate the ﬁne balance between high- and low-
expressing HLA-G haplotypes [61]. It is noteworthy that
the majority of SNPs described in the promoter region are
located in transcriptional factor binding-sites (Fig. 4, lower
panel), so heterozygosis in these regions may strongly
affect the promoter responsiveness to several transcrip-
tional factors. In addition, the 30UTR seems to undergo the
same pattern of selective pressure of the promoter region.
The two most common 3’UTR haplotypes found in highly
genetically diverse populations, such as Brazilians, differ
in 5 out of 8 points of variation, including those already
described inﬂuencing HLA-G expression (14-bp, ?3142
and ?3187). Given that, and considering that both present
frequencies of approximately 25% [82], one may assume
that this region may also suffer balancing selection.
The within-species peculiarities of MHC-G genes in
primates (not following a linear evolutionary pattern)
Fig. 11 MHC-G molecule (a1, a2 and a3 domains) in primates.
a Gorilla gorilla: only one MHC-G allele was found; b Pan
troglodytes: one variable position and two different MHC-G alleles
were found; and c Pongo pygmaeus: MHC-G alleles found in variable
positions in ﬁve orangutans. Variable amino acid positions are
indicated in circles for each domain cluster (codons)
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fetal-maternal relationships that may shape MHC-G evo-
lution. For instance, cotton-top tamarins always give birth
to monozygotic twins, which thereafter cling to the father
and are born to long-lasting monogamous couples. All
other primates are polygamous (polygamy, especially in
primitive societies, is a human characteristic), and mothers
may be in contact with many different fetuses regarding
MHC antigens. However, Cercopithecinae and orangutans
(species less exposed to allogeneic fetuses) are the most
polymorphic at the MHC level [101]. A hypothesis may be
raised that a mechanism avoiding a high MHC-G allelism
has been developed in polygamous species (Old World and
anthropoid monkeys and humans). This would protect the
mother against frequently MHC incompatible trophoblast
aggression (as seen in some pregnancy-related tumors) and,
on the other hand, would confer to the mother a simple
non-polymorphic system to switch off fetal NK and other
immune system cells [17].
Since each primate species seems to have undergone a
particular evolutionary pathway, further research studies
are needed to understand the MHC-G 40 million year
evolution, as summarized in this paper.
Population genetics in humans
As per deﬁnition, a polymorphic site must be present in a
population at a frequency higher than 1%; however, some
HLA-G variation sites may not be considered true poly-
morphisms, since they are observed in just one or in a few
individuals. Among the 13 SNPs described for exon 2, 12
for exon 3 and 8 for exon 4, apparently only four SNPs
(one in exon 2, two in exon 3 and one in exon 4) do present
frequencies higher than 1% in worldwide populations [31,
82, 89, 105, 110–116]. The majority of these SNPs are
synonymous substitutions, and only one non-synonymous
substitution in each of exons 2, 3 or 4 does present a fre-
quency higher than 1% in worldwide populations [31, 82,
89, 105, 110–115].
Regarding the consensus allele family (G*01:01), only 4
variation sites in the coding region of the HLA-G locus are
related to amino acid exchange, which is frequently found
in worldwide populations: (1) the ?292 A ? T SNP at
exon 2 (codon 31), exchanging a threonine for serine,
characteristic of the G*01:03 allele; (2) the ?755 C ? A
SNP at exon 3 (codon 110), exchanging leucine/isoleucine,
typical of the G*01:04 allele group; (3) the DC deletion at
exon 3, typical of the G*01:05 N allele; and (4) the ?1799
C ? T SNP (codon 258), exchanging threonine for
methionine, characteristic of the G*01:06 allele. In prac-
tical terms, with exception made for the null alleles, only
four different HLA-G proteins are usually observed in
worldwide populations, which are encoded by the most
frequent G*01:01, G*01:03, G*01:04 and G*01:06 allele
families (Table 1), and which may inﬂuence HLA-G
function (Fig. 2).
It is interesting to observe that the DC deletion charac-
teristic of the G*01:05N allele [12] is frequently found in
some populations and absent in others [108, 111, 117],
being overrepresented in North Indian (15.4%) and African
Shona (11.1%) populations compared to Danish (1.0%) and
Brazilian (0.97–4.17%) populations. In addition, the
G*01:03 allele is overrepresented in North Indian (24.2%)
compared to African Shona (7.4%) and Danish (4%) pop-
ulations (Table 1).
Considering all alleles described for the coding region of
the HLA-G gene, at least 24 exhibit a particular substitution
detected only in a single or in a few individuals (Table 1).
In fact, the number of detected HLA-G alleles in distinct
samples from different regions is frequently less than the
total number [82, 89, 105, 108, 111, 118–122]. Even in
highly admixed populations, such as Brazilians, only 19
out of the 44 HLA-G alleles were detected considering two
different samples, 3 of them being observed only in single
individuals [82, 105, 113, 123].
Overall, the low protein variability observed for the
HLA-G gene corroborates evidence of its evolutionary
pathway.
HLA-G polymorphism and disease associations
HLA-G expression has been extensively evaluated in sev-
eral disorders of distinct etiologies; however, HLA-G gene
polymorphism has not been studied to the same extent.
Since the magnitude of HLA-G expression is regulated by
the promoter and 30 untranslated regions, many studies
have focused on these regions, particularly on the 30UTR
polymorphic sites. In this section, we selected some dis-
orders in which the tolerogenic role of HLA-G has been
implicated on disease susceptibility, outcome or both,
excluding pregnancy disorders, which will be discussed in
another part of this series of HLA-G reviews.
Chronic viral infections
Viruses have evolved multiple strategies to subvert host
immune surveillance and responses. Strategies such as the
downregulation of classical MHC class I antigen prevent
the display of viral peptides to escape lymphocyte T
cytolysis [124]. In principle, virus-infected cells exhibiting
downregulation of MHC class I molecules should be vul-
nerable to natural killer (NK) cell-mediated cytolysis.
However, viruses have developed various mechanisms to
impede NK cell recognition by inducing expression of
HLA-G molecules [125, 126], which can suppress the
HLA-G polymorphisms and functional implications 383Table 1 Frequencies of the HLA-G coding region alleles observed in selected populations
Allele African
Shona
African
American
African
Guanaian
Brazilians
(Southeast)
Cohort 1
Brazilians
(Southeast)
Cohort 2
North
India
c
Polish
d Hutterite Danish German Japanese Chinese
Han
c
G*01:01:01:01 37.96 70.23 83.33 39.81 24.54
a 10.00 52.00 46.00 56.00 32.10 33.00 37.32
G*01:01:01:02 –
G*01:01:01:03 0
G*01:01:01:04 7.41
G*01:01:01:05 11.11
G*01:01:01:06 –
G*01:01:02:01 15.74 5.95 2.38 19.90 15.28 16.25 30.50 20.00 25.00 36.30 16.00 11.64
G*01:01:02:02 0
G*01:01:03:01 – 2.38 0 5.34 3.70 5.00 5.00 2.00 5.00 6.80 6.00 20.20
G*01:01:03:02 –
G*01:01:04 – – – 0.49 0 7.50 0 4.40 0 – – –
G*01:01:05 – – – 0 0.46 0 0 – 0 – – –
G*01:01:06 – – – 0.97 0 – 4.00 – – – – –
G*01:01:07 – – – 0 0 0 0 – 0 1.90 – –
G*01:01:08 6.94 – – 4.37 0.93 0 4.50 – 1.00 9.10 – 5.48
G*01:01:09 – – – 0 0.46 – 1.00 – – – – –
G*01:01:11 – – – 0.49 0 – 0 – – – – –
G*01:01:12 – – – 0 0 – 0 – – – – –
G*01:01:13 – – – 0 0 – 0 – – – – –
G*01:01:14 – – – 0 0.46 – 0 – – – – –
G*01:01:15 – – – 0 0 – 0 – – – – –
G*01:01:16 – – – 0 0 – 0 – – – – –
G*01:01:17 – – – 0 0 – 0 – – – – –
G*01:01:18 – – – 0 0 – 0 – – – – –
G*01:01:19 – – – 0 0 – 0 – – – – –
G*01:02 – – – 0 0 1.25 0 – 0 – – –
G*01:03 7.41 – – 8.74 8.80 24.17 0 2.70 4.00 2.30 – 0.34
G*01:04:01 20.83 13.10 9.52 8.25 4.63 17.50 2.00 13.00 9.00 6.10 45.00 18.49
G*01:04:02 – – – 0 0 – 0 – – – – 2.40
G*01:04:03 – – – 0 0.46 – 0 – 0 – – 2.74
G*01:04:04 – – – 3.88 3.24 – 0 – – – – –
G*01:04:05 – – – 0 0 – 0 – – – – –
G*01:05 N 11.11 8.33 4.76 0.97 4.17 15.42 1.50 – 1.00 2.30 – 1.37
G*01:06 – – – 4.85 6.48 2.92 0 – – – – –
G*01:07 – – – 0 0 – 0 – – – – –
G*01:08 – – – 0 0 – 0 – – – – –
G*01:09 – – – 0.49 0 – 0 – – – – –
G*01:10 – – – 0 0 – 0 – – – – –
G*01:11 – – – 0 0 – 0 – – – – –
G*01:12 – – – 0 0 – 0 – – – – –
G*01:13 N – – – 0 0 – 0 – – – – –
G*01:14 – – – 0 0 – 0 – – – – –
G*01:15 – – – 0 0 – 0 – – – – –
G*01:16 – - – 0 0 – 0 – – – – –
Others – – – 1.45 7.41
b – – 12.00 – – – –
384 E.A. Donadi et al.function of various immune cells [127–129]. The immu-
nosuppressive properties of HLA-G might contribute to the
susceptibility and persistence of viral infections.
Studies looking at the association between HLA-G
expression and HIV-1 infection have yielded contradictory
results. Increased soluble HLA-G levels [130] and
increased surface expression of HLA-G on monocytes and
T lymphocytes [126] were observed in antiretroviral
(ART)-treated HIV-1-infected European Caucasians. In
contrast, low levels of plasma soluble HLA-G were asso-
ciated with HIV-1 infection in ART-naive Beninese
commercial sex workers (CSW) [131]. The discrepancies
observed in these studies may be due to several reasons:
ﬁrst, ART can induce surface expression of HLA-G on
blood peripheral monocytes from HIV-1-infected patients
[132, 133]. Hence, the relatively high blood levels of HLA-
G observed in the European subjects could be due to ART
and not to HIV-1 infection per se. Second, previous studies
[126, 130] did not control for potential confounding factors
that could inﬂuence HLA-G expression. Blood levels of
soluble HLA-G are lower in men than in non-pregnant
women [134], and during pregnancy the levels increase
even more [135]. Third, cytokine production could inﬂu-
ence HLA-G expression and vice versa. Interleukin (IL)-10
has been shown to induce HLA-G expression [136], and
HLA-G can also stimulate IL-10 expression in peripheral
blood monocytes [137]. Interestingly, plasma levels of
IL-10 were lower in HIV-1-infected CSWs compared to
both the HIV-1-uninfected CSW and non-CSW groups
[138]. Fourth, HLA-G expression may ﬂuctuate over the
course of infection and may vary between different rates of
disease progression. Indeed, longitudinal monitoring of
plasma-soluble HLA-G levels in subjects with acute HIV
infection undergoing different rates of disease progression
showed that levels were elevated in the early phases of
infection for all patients and remained high throughout
follow-up in rapid progressors who responded to ART;
however, soluble HLA-G were restored to normal levels in
the chronic phase of infection in both untreated normal
progressors and long-term nonprogressors [139]. Finally,
HLA-G gene polymorphism has to be taken into account
since healthy individuals carrying the HLA-G*01:01:03
and G*01:05 N alleles have lower plasma-soluble HLA-G
levels than subjects carrying the more frequent
HLA-G*01:01:01 allele. In addition, individuals with the
latter allele have lower plasma soluble HLA-G levels than
those with the HLA-G*01:04:01 allele [84]. Moreover, the
presence of a 14-bp sequence insertion in HLA-G 30UTR
has been associated with signiﬁcantly reduced HLA-G
mRNA levels [87] and lower levels of soluble HLA-G in
the serum of healthy subjects [63, 140]. In the study of
CSWs from Benin, all subjects were non-pregnant women,
and their reduced expression of soluble HLA-G in plasma
was independently associated with both HIV-1 infection
and the HLA-G 30UTR 14-bp sequence insertion homozy-
gote genotype [131].
HLA-G polymorphism is also associated with the risk
of human immunodeﬁciency virus (HIV) infection.
Indeed, the HLA-G*01:05N allele was signiﬁcantly asso-
ciated with protection from HIV-1 infection, whereas the
HLA-G*01:01:08 allele was associated with an increased
risk of HIV-1 infection in Zimbabwean women [141,
142].
Since the HLA-G*01:05N allele does not encode com-
plete HLA-G1 proteins [107], and since HLA-G1 is a
major ligand by which HLA-G inhibits NK cell-mediated
lysis [143], it has been postulated that the absence or
reduced expression of HLA-G1 molecules in individuals
carrying the HLA-G*01:05N allele would allow NK cells to
destroy HIV-infected cells, leading to protection from
infection. The HLA-G*01:01:08 allele is deﬁned by a
synonymous substitution (proline) at codon 57. Although
discordance in HLA-G codon 57 between a mother and her
child has been reported to reduce the risk of HIV-1 vertical
transmission in American Caucasians [144], this ﬁnding
was not conﬁrmed in the Zimbabwean population [145].
Because the polymorphism in codon 57 does not change
the HLA-G amino acid composition and presumably its
Table 1 continued
Allele African
Shona
African
American
African
Guanaian
Brazilians
(Southeast)
Cohort 1
Brazilians
(Southeast)
Cohort 2
North
India
c
Polish
d Hutterite Danish German Japanese Chinese
Han
c
2n 216 84 84 206 216 240 200 160 104 264 108 292
Reference [108][ 118][ 118][ 105][ 82][ 111][ 119][ 120][ 89][ 121][ 89][ 122]
a The alleles G*01:01:01:01 and G*01:01:01:02 were pooled together
b This amount is due to typing ambiguities, not new alleles
c Group of fertile women
d Group of all individuals with in vitro fertilization
‘‘–’’ Denotes an allele that was not evaluated
HLA-G polymorphisms and functional implications 385function, it is difﬁcult at this time to envisage the mecha-
nism by which such a silent mutation could have a direct
inﬂuence on HIV transmission.
In addition, two independent studies have found an
association between HLA-G nucleotide sequences located
in the 30UTR, including the C variant at position ?3010
(others consider this position as ?3777) and 14-bp deletion
polymorphism, and decreased risk of HIV-1 vertical
transmission [146, 147]. Moreover, two independent stud-
ies have demonstrated that the ?3010 and 14-bp
polymorphisms are in linkage disequilibrium, especially
the association between the 14-bp insertion and the
?3010C allele [82, 148]. The 3010C variant alone has no
effect on vertical transmission of HIV-1 but, when linked
with the 14-bp deletion allele, exerts a positive role on
protection [148].
Associations between HLA-G polymorphism and other
chronic viral infections have also been described. Mar-
tinetti et al. [149] observed that the HLA-G 30UTR 14-bp
deletion homozygote genotype and the presence of the
HLA-G*01:04:01 allele that contains this deletion were
both risk factors for vertical transmission of hepatitis C
virus (HCV), whereas the HLA-G*01:05N allele con-
taining the 14-bp insertion polymorphism was associated
with reduced risk of transmission. Homozygosity for the
C variant at position ?3142 in the HLA-G 30UTR region
conferred protection against HCV infection among sickle
cell disease patients [150]. Interestingly, the HLA-
G 30UTR ?3142 variant is in linkage disequilibrium
with the 14-bp polymorphism and is thought to affect
microRNA binding to the mRNA molecule, thus inﬂu-
encing HLA-G RNA turnover and translation [81, 82].
During acute human cytomegalovirus (hCMV) infection
both membrane-bound and soluble HLA-G expression is
upregulated in peripheral blood monocytes and bron-
choalveolar macrophages [125, 151]. The HLA-G 14-bp
deletion homozygote genotype was associated with acute
hCMV infection in children and higher hCMV DNA
copy numbers in the urine of these children [152].
In neurotropic viral infections, herpes simplex virus type
1 and rabies virus upregulate the neuronal expression of
HLA-G isoforms in both infected cells and neighboring
uninfected cells [153]. Cell surface expression of HLA-G
was restricted to rabies virus-infected neurons [154];
however, there are no HLA-G polymorphism studies in
these disorders.
Taken together, these observations suggest that, in the
context of viral infections, the expression of HLA-G is a
complex process modulated by many factors such as HLA-
G polymorphism, stage of infection, drug therapy, and
cytokine expression patterns, which may contribute to an
immunological environment affecting the outcome of
infection.
Transplantation
Due to the scarcity of organs for transplantation, and due to
the several mechanisms that contribute to graft rejection,
much effort has been devoted to understanding the mech-
anisms associated with graft rejection and survival. Since
the discovery in the 1990s that HLA-G played a relevant
physiological role in the induction of maternal-fetal toler-
ance, the idea of investigating the role of HLA-G in
allografting has taken hold. Several studies have been
reported demonstrating that the presence of HLA-G in the
allograft [155–158] or the increase of soluble HLA-G
serum/plasma levels [159–166] are associated with better
graft acceptance, increased graft survival or both.
Despite the large amount of information regarding the
graft expression or the levels of soluble HLA-G, few
studies have been conducted evaluating polymorphic sites
in the HLA-G gene, most of them evaluating only the 14-bp
INDEL polymorphism in the 3’UTR. In kidney transplan-
tation, the frequency of the 14-bp insertion/deletion alleles
or genotypes revealed no signiﬁcant differences when
patients were compared to healthy controls, either in a
Brazilian [167] or in an Italian cohort of patients [168];
however, the frequency of the 14-bp insertion homozygous
genotype was increased in patients exhibiting acute rejec-
tion [167]. Similarly, in bone marrow transplantation for
thalassemia, the 14-bp deletion homozygous genotype was
associated with a higher risk of developing acute graft-
versus-host disease [169]. In contrast, for heart transplants,
the 14-bp deletion homozygous genotype has been asso-
ciated with higher levels of soluble HLA-G and higher
bioavailability of cyclosporine [170]. Although the 14-bp
insertion has been associated with a more stable mRNA
[70], a fraction of HLA-G mRNA transcripts presenting the
14-bp insertion homozygous genotype has been associated
with a lower production of HLA-G [63, 87]. According to
these ﬁndings, the results regarding 14-bp INDEL poly-
morphism in transplantation are coherent, indicating that
insertion homozygous genotypes (associated with
decreased production of HLA-G) are associated with
rejection or acute graft-versus-host disease, whereas the
deletion homozygous genotype (associated with increased
production) is associated with low rejection.
Besides the 30UTR, the coding region polymorphism has
also been studied in renal transplant patients. It has been
well recognized that HLA-A-B and -DR incompatibilities
are associated with a poorer prognosis and shorter allograft
survival; however, little attention has been paid to HLA-
G locus incompatibility between donor and receptor, par-
ticularly considering that the HLA-G molecule is not a
recognized peptide presenter molecule. On the other hand,
the HLA-G locus is in linkage disequilibrium with the
HLA-A locus, and the molecule has well-recognized
386 E.A. Donadi et al.tolerogenic features. The presence of two HLA-G matches
was associated with lower risk of kidney rejection when
compared to zero or one match. In addition, patients who
were heterozygous for the HLA-G alleles exhibiting
synonymous/non-synonymous (S/NS) nucleotide variations
had a higher chance to develop rejection in relation to those
homozygous for S/S or NS/NS alleles [113]. Since
HLA-G alleles exhibiting synonymous nucleotide variation
may have distinct promoter or 30UTR, this study supports
the importance of studying regulatory HLA-G regions to
understand the genetic mechanism associated with the
production of HLA-G in transplants.
Autoimmune disorders
Autoimmune disorders encompass a heterogeneous group
of diseases, exhibiting complex genetic inheritance,
affecting virtually all organs or tissues, and producing a
vast array of clinical features. Breakdown of the mecha-
nisms that control central or peripheral tolerance in
genetically susceptible individuals, usually triggered by
environmental factors, is the major pathogenetic feature. In
addition, many of these diseases share several suscepti-
bility genes, particularly those encoded by MHC. Since
classical HLA class I and II molecules are highly impli-
cated in peptide presentation, and since disturbances of the
MHC/peptide/T cell receptor interaction may drive the
production of auto-reactive T lymphocytes or auto-reactive
autoantibodies, the genes that encode these molecules have
been the primary candidates associated with susceptibility
to or protection against the development of autoimmunity.
Besides MHC, some genes encoding molecules responsible
for the negative control of the immune response, including
CTLA-4, PTPN-22 and correlated genes, have been asso-
ciated with distinct autoimmune disorders like systemic
lupus erythematosus, rheumatoid arthritis, multiple scle-
rosis and type 1A diabetes mellitus [171–173]. Given that
autoimmunity is caused by a breakdown of tolerance and
HLA-G is as a tolerogenic molecule, HLA-G should be an
adequate subject; however, little attention has been given
to HLA-G tissue expression or genetic aspects.
Considering that the presence of soluble isoforms or
HLA-G expression on affected tissue cells should lessen
autoimmune manifestations, only few examples have
shown such association. Tissue HLA-G expression has
been observed in the skin of patients with systemic scle-
rosis, who exhibited a lower frequency of vascular
cutaneous lesions, telangiectasias, inﬂammatory polyar-
thritis and increased survival after a 15-year follow-up
[174]. In the demyelinating disorder multiple sclerosis,
levels of soluble HLA-G in the cerebrospinal ﬂuid of
patients have been inversely associated with imaging
ﬁndings indicative of disease activity [175]. Soluble HLA-
G levels were increased in patients with systemic lupus
erythematosus in relation to controls; however, no corre-
lation with disease activity was observed [176].
With respect to polymorphic sites in the HLA-G gene,
no association was found regarding the frequencies of the
-725C/G (promoter region), exon 3 positions 129 and 130
DC (coding region), and 14-bp INDEL (30UTR) in multiple
sclerosis patients [73]. Increased frequencies of the 14-bp
insertion allele as well as the insertion/insertion genotype
were observed in systemic lupus erythematosus patients
[115], whereas the heterozygous insertion/deletion geno-
type was associated with the disease activity index,
photosensitivity and absence of arthritis [177]. The 14-bp
deletion allele was overrepresented in patients exhibiting
the juvenile form but not the adult form of rheumatoid
arthritis, presenting no association with diseased severity or
clinical manifestations [178]. In addition, the 14-bp inser-
tion/insertion genotype was associated with increased
production of soluble HLA-G levels and a better thera-
peutic response to methotrexate in adult rheumatoid
arthritis patients [179].
Agnostic studies using genome-wide screens or ﬁne
mapping of the MHC region, conducted on large numbers
of multiplex families, have unexpectedly identiﬁed the
HLA-G region as a susceptibility gene for type 1 diabetes
mellitus [180] and for bronchial asthma, which is an
immune-mediated chronic inﬂammatory disease [68]. The
risk conferred by HLA-G for diabetes mellitus patients was
independent of that conferred by the well-recognized
classical class II HLA-DRB1, DQB1 and DQA1 alleles
[181, 182]. The association of bronchial asthma with
HLA-G has led investigators to evaluate the promoter and
30UTR of the gene, reporting that the GG genotype of the
-964G/A SNP was associated with asthma in children of
affected mothers, whereas the AA genotype was associated
with asthma in children of unaffected mothers, as previ-
ously mentioned [68]. In addition, the authors identiﬁed the
SNP ?3142C/G at the 30UTR as a putative target site for
miRNAs, strengthening the association of HLA-G and
asthma [81].
Taken together, these ﬁndings seem to associate
HLA-G polymorphic sites with autoimmune disorders
encompassing functional sites of the gene, i.e., the pro-
moter and 30untranslated regions.
Tumors
Cancer cells display tumor-associated antigens coded by
mutated or normal deregulated genes that, once presented
by classical MHC class I molecules, may be recognized by
the host immune system, being usually eliminated. Even in
the presence of a competent immune system, neoplastic
cells can grow and progress to very aggressive malignant
HLA-G polymorphisms and functional implications 387lesions, evolving by tumor immunoediting, a process that
comprises three major mechanisms. First, most immuno-
genic tumor cells are eliminated by cytotoxic T and NK
cells. Second, tumor cells with reduced immunogenicity
are selected. Third, variants that no longer respond to the
host immune system are maintained [183–185]. HLA-G is
supposed to play a pivotal role in cancer immunoediting by
decreasing the elimination of tumor cells, inhibiting the
cytotoxic function of T and NK cells, and by trogocytosis,
i.e., the intercell transference of viable HLA-G molecules,
rendering competent cytotoxic cells unresponsive to tumor
antigens [186, 187].
The most common immune-escape mechanism in
experimental or spontaneous tumors is the downregulation
or lack of expression of classical HLA class I molecules,
which directly affects cytotoxic T cell function against
tumor cells. The loss of classical class I molecules is often
associated with mutation in the b2-microglobulin gene,
which may affect class I expression level, producing
unstable molecules. In addition, the loss of certain classical
HLA class I alleles by microdeletions may lead to inefﬁ-
cient presentation of some immunodominant antigens
[188]. In the absence of classical HLA class I molecules,
NK cells become the major actors for tumor elimination.
Similar to chronic viral infections, the microenvironment
of the tumor or the transformed cell per se may induce
HLA-G expression, impairing the activity of NK cells.
Several studies have demonstrated that various tumor
lesions do present HLA-G transcription and protein
expression [183]. To date, HLA-G expression has been
detected in several tumor cells, exhibiting distinct patterns
regarding the percentage of lesions expressing the mole-
cule. Exemplifying, in cutaneous melanomas [189, 190],
renal cell carcinomas [191], retinoblastomas [192], colo-
rectal cancer [193], ovarian carcinomas [194, 195],
endometrial adenocarcinomas [196], gastric cancer [197,
198], cutaneous T cell lymphomas [199, 200] and pan-
creatic ductal adenocarcinoma [201], among others [17,
202], at least 30% of these lesions exhibit HLA-G
expression. In addition to tumor cell expression, HLA-G
may also be detected in tumor inﬁltrating cells [183],
which, allied to increased soluble HLA-G concentrations
[203–206], may contribute to tumor progression.
Overall, most studies have evaluated HLA-G expression
in tumor cells, tumor cell lines or even soluble HLA-G
levels, and few genetic studies have been performed.
Underlying these tumor-associated studies is the concept
that some HLA-G polymorphisms may inﬂuence HLA-G
expression (promoter and 30UTR polymorphisms), the
pattern of alternative splicing of the primary transcript and
mRNA turnover (coding region, including introns, and
30UTR polymorphisms). The regulatory sequences of the
HLA-G gene, as discussed earlier, may be induced by
various factors present in the tumor microenvironment
[207], since tumor-derived soluble factors may promote
HLA-G expression [183]. Several lines of evidence have
shown that the methylation status of the HLA-G gene
promoter is also crucial for the gene transcriptional activity
[66, 67], and polymorphisms located at CpG sites sur-
rounding the HLA-G locus may affect the gene methylation
pattern [64]. Regarding the 30UTR and coding region, the
14-bp insertion seems to occur at high frequency in renal
cell carcinomas compared to the normal kidney epithelium;
however, no correlation between the 14-bp INDEL poly-
morphism and the level of HLA-G expression has been
found [191].
In human papillomavirus (HPV) infections, the coding
region G*01:03 and the G*01:04 alleles were associated
with squamous intraepithelial lesions (SIL), and the
G*01:01/G*01:04 genotype was associated with high-
grade lesions (HSIL). In addition, patients possessing the
extended G*01:04/?14-bp haplotype and harboring HPV-
16 and -18 co-infections were particularly susceptible to
HSIL [208].
In bladder cancer, the HLA-G locus was associated with
susceptibility to transitional cell carcinoma (TCC) devel-
opment and progression. The G*01:04 allele family
(especially the G*01:04:04 allele) and the G*01:03 allele
were associated with a tobacco-dependent inﬂuence on
TCC development. The G*01:04 allele family was asso-
ciated with progression to high-grade bladder tumor,
irrespective of the smoking habit, while the G*01:03 allele
was associated with protection against TCC [123]. Curi-
ously, the same HLA-G coding region variations were
found to inﬂuence both HPV-induced lesions and bladder
cancer in studies conducted on two different samples of
patients from the same geographical area (Southeast Bra-
zil). Apparently, the G*01:04 allele family (G*01:04:01
and G*01:04:04 being the most frequent alleles in Brazil-
ians), which is often associated with HSIL, has also been
associated with increased production of soluble HLA-G
[84]. This is of particular importance since the G*01:04
allele family occurs at high frequency in Brazilians (about
12%) [105], as well as in worldwide populations studied so
far, including African Shona (about 21%) [110], North
Indians (about 17.5%) [111] and Danes (about 9%) [89].
The higher expression of HLA-G associated with the
G*01:04 allele family is probably due to the presence of
speciﬁc 50 [61]o r3 0UTR [82] haplotypes that are exclusive
of these alleles. The G*01:04 allele family presents the
same 30UTR haplotype, encompassing two polymorphic
sites previously associated with low HLA-G expression,
?3187A and ?3142G [82]. In contrast, this family presents
a unique promoter haplotype characterized by the presence
of -1155A close to the locus control region (LCR), sharing
speciﬁc combinations of polymorphic sites at several
388 E.A. Donadi et al.transcriptional factor binding sites [61]. Thus, it is possible
that this promoter region segment may be responsible for
the increased HLA-G production.
Knowledge of the tumor cell HLA-G expression proﬁle
as well as the typing of relevant polymorphic sites in the
HLA-G gene may discriminate patients prone to producing
high amounts of HLA-G, individualizing future treatments
targeting HLA-G.
Concluding remarks
In physiological conditions like pregnancy, the expression
of HLA-G is useful to maintain tolerance of the semial-
logeneic engraftment. In pathological conditions, the
expression of HLA-G may be proﬁtable or pernicious,
depending on the speciﬁc disorder. Even considering
individuals exhibiting the same type of disorder, some may
express HLA-G, while others may not. Certainly, gene
regulatory regions play a pivotal role in this process, and
polymorphic sites observed in these regions may inﬂuence
HLA-G production.
Whether or not a sick individual will express HLA-G
depends on several factors: (1) transcriptional factors in
the disease milieu that upregulate HLA-G expression; (2)
presence of selected polymorphic sites in the promoter
region that can be targeted for transcription factors; (3)
magnitude of post-transcriptional factors that may degrade
HLA-G mRNA, particularly, microRNAs that can target
polymorphic sites at 30UTR; (4) structural features of the
HLA-G molecule encoded by the alleles of that person,
which are available to interact with HLA-G receptors; (5)
intrinsic features of diseased tissue cells; (6) polymorphic
sites on genes that encode the mediators involved in the
pathogenesis of the disease; (7) the role of neighboring or
distant genes epistatically acting on the HLA-G gene; and
(8) the role of epigenetic factors, among others. Therefore,
due to the complexity of this scenario, most studies have
focused only on one or a few of these aspects, adding just
a few scenes to a long motion picture that needs to be
edited to show the epilogue. Much has to be learned
regarding the regulation of HLA-G expression, to unveil
individuals at risk to develop complications associated
with the excess or scanty HLA-G production to individ-
ualize speciﬁc therapeutical approaches furnishing or
inhibiting HLA-G.
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